medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2021, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2021; 41 (3)

Advanced chronic kidney disease in elderly under renal replacement therapy and conservative treatment. Comparative Survival and symptoms study

Rubio RMV, Lou ALM, Gimeno OJA, Hernández MP, Martínez PE, Lambán IE

Language: Spanish
References: 29
Page: 173-183
PDF size: 166.12 Kb.


ABSTRACT

Introduction: Despite the high prevalence of advanced chronic kidney disease for elderly, survival and symptom burden are uncertain for patients commencing renal replacement therapy versus patients managed with supportive care without dialysis (RSC-NFD). We examined these outcomes in both treatment modalities. Methods: Prospective cohort study of RSCNFD and renal replacement therapy patients older than 75-years-old. A survival analysis and Symptoms were measured using POS-S Renal Scale in a multidisciplinary RSC-NFD clinic and in renal replacement therapy units. Results: 82 RSC-NFD patients and 37 renal replacement therapy patients were included in the study. RSC-NFD patients presented significant comorbidity (Charlson) and worse functional situation (Karnofsky). Median survival in the RSC-NFD treatment was 26.9 months (95%CI 19.6-34.2) vs mean 30.5 months (95% CI 27.46-33.67) in renal replacement therapy group (p 0.014 in favour of dialysis). Both treatments presented a wide variety of symptoms, being weakness the most prevalent and intense in both groups (97% renal replacement therapy and 98% RSC-NFD). The evaluation at 0,12 and 24 months showed that the number and intensity of symptoms remained stable in both therapies and there were no clinical differences. Conclusions: Dialysis is associated with a survival advantage from RSC-NFD. However, the perceived symptoms in advanced chronic kidney disease are highly prevalent and we didn`t appreciate differences comparing both treatments. Routine symptom assessment by a multidisciplinary team can be useful in clinical practice of patients in renal replacement therapy and RSC-NFD.


REFERENCES

  1. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in Prevalence of Chronic Kidney Disease in the United States. Ann Intern Med. 2016;165(7):473-81. doi: 10.7326/M16-0273.

  2. Sociedad Española de Nefrología. Registro Español de Enfermos Renales. Informe de diálisis y trasplante 2019 [Internet]. Disponible en: https://www.senefro.org/contents/webstructure/INFORME_REER_SEN_2020_WEB_SEN.pdf (consulta: 24-06-2021).

  3. Otero A, de Francisco A, Gayoso P, García F; EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología (Madr.) 2010;30(1):78-86. doi: 10.3265/Nefrologia.pre2009.Dic.5732.

  4. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332(7541):563-4. doi: 10.1136/bmj.332.7541.563.

  5. Walker SR, Gill K, Macdonald K, Komenda P, Rigatto C, Sood MM, et al. Association of frailty and physical function in patients with non-dialysis CKD: a systematic review. BMC Nephrol. 2013;14:228. doi: 10.1186/1471-2369-14-228.

  6. Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract. 2009;111(1):c74-80. doi: 10.1159/000183177.

  7. Murtagh FE, Addington-Hall JM, Edmonds PM, Donohoe P, Carey I, Jenkins K, et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med. 2007;10(6):1266-76. doi: 10.1089/jpm.2007.0017.

  8. Gutiérrez Sánchez D, Leiva-Santos JP, Sánchez-Hernández R, Gómez García R. Prevalencia y evaluación de síntomas en enfermedad renal crónica avanzada. Enferm Nefrol. 2015;18(3):228-36. doi: 10.4321/S2254-28842015000300010.

  9. Gutiérrez Sánchez D, Leiva-Santo JP, Macías López MJ, Cuesta Vargas AI. Perfil sintomático de los pacientes con enfermedad renal crónica estadio 4 y 5. Enferm Nefrol. 2017;20(3):259-66. doi: 10.4321/S2254-28842017000300010.

  10. Davison SN, Jassal SV. Supportive care: integration of patient-centered kidney care to manage symptoms and geriatric syndromes. Clin J Am Soc Nephrol. 2016;11(10):1882-91. doi: 10.2215/CJN.01050116.

  11. Manns B, Hemmelgarn B, Lillie E, Dip SC, Cyr A, Gladish M, et al. Setting research priorities for patients on or nearing dialysis. Clin J Am Soc Nephrol. 2014;9(10):1813-21. doi: 10.2215/CJN.01610214.

  12. Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, et al.; Kidney Disease: Improving Global Outcomes. Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney Int. 2015;88(3):447-59. doi: 10.1038/ki.2015.110.

  13. O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med. 2012;15(2):228-35. doi: 10.1089/jpm.2011.0207.

  14. Buades JM, Losada P, Bernabeu R, Roig L, Schneider P, Sansó N, et al. Guía para el tratamiento conservador en pacientes con enfermedad renal crónica avanzada (ERCA). Palma de Mallorca: Programa de Cuidados Paliativos de las Islas Baleares, 2015. Disponible en: https://www.caib.es/sites/curespalliatives/f/190069 (consulta: 24-06-2021).

  15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.

  16. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46(4):M139-44. doi: 10.1093/geronj/46.4.m139.

  17. Gutiérrez-Sánchez D, Leiva-Santos JP, Sánchez-Hernández R, Hernández-Marrero D, Cuesta-Vargas AI. Spanish modified version of the palliative care outcome scale-symptoms renal: cross-cultural adaptation and validation. BMC Nephrol. 2016;17(1):180. doi: 10.1186/s12882-016-0402-8.

  18. Joly D, Anglicheau D, Alberti C, Nguyen AT, Touam M, Grünfeld JP, et al. Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes. J Am Soc Nephrol. 2003;14(4):1012-21. doi: 10.1097/01.asn.0000054493.04151.80.

  19. Carson RC, Juszczak M, Davenport A, Burns A. Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc Nephrol. 2009;4(10):1611-9. doi: 10.2215/CJN.00510109.

  20. Gutiérrez Sánchez D, Leiva-Santos JP, Macías López MJ, Cuesta-Vargas AI. Prevalencia de síntomas en enfermedad renal crónica avanzada. Nefrología (Madr.) 2018;38(5):558-72. doi: 10.1016/j.nefro.2017.11.021.

  21. Rebollo P, Mon C, Álvarez-Ude F, Vázquez A, Fernández Reyes MJ, Sánchez R. Síntomas físicos y trastornos emocionales en pacientes en programa de hemodiálisis periódicas. Nefrología (Madr.) 2001;21(2):191-9.

  22. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82-99. doi: 10.1053/j.ackd.2006.10.001.

  23. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82-99. doi: 10.1053/j.ackd.2006.10.001.

  24. Portilla Franco ME, Tornero Molina F, Gregorio PG. La fragilidad en el anciano con enfermedad renal crónica. Nefrología (Madr.) 2016;36(6):609-15. doi: 10.1016/j.nefro.2016.03.020.

  25. Walker SR, Wagner M, Tangri N. Chronic kidney disease, frailty, and unsuccessful aging: a review. J Ren Nutr. 2014;24(6):364-70. doi: 10.1053/j.jrn.2014.09.001.

  26. Yong DS, Kwok AO, Wong DM, Suen MH, Chen WT, Tse DM. Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat Med. 2009;23(2):111-9. doi: 10.1177/0269216308101099.

  27. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057-64. doi: 10.2215/CJN.00430109.

  28. Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2011;6(2):326-33. doi: 10.2215/CJN.04770610.

  29. Brown MA, Collett GK, Josland EA, Foote C, Li Q, Brennan FP. CKD in elderly patients managed without dialysis: survival, symptoms, and quality of life. Clin J Am Soc Nephrol. 2015;10(2):260-8. doi: 10.2215/CJN.03330414.




2020     |     www.medigraphic.com